CollPlant Biotechnologies LtdCLGN
Price (close)
$4.25
Market cap
$8.0M
P/E
—
Revenue (FY)
$2.4M
Net income
-$11.5M
Dividend yield
—
1-year total return
-85.0%
Net margin
-484.6%
Revenue growth
360.4%
Debt / equity
—
What CollPlant Biotechnologies Ltd does.
aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs. Our products are based on our recombinant
human collagen (rhCollagen) that is produced in genetically engineered tobacco plants using our proprietary technology. These products
address indications for the diverse fields of tissue repair and aesthetics, and are ushering in a new era in regenerative and aesthetic
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.1M | $15.6M | $299,000 | $11.0M | $515,000 | $2.4M |
| Net income | -$5.8M | $237,000 | -$16.9M | -$7.0M | -$16.6M | -$11.5M |
| Free cash flow | -$4.9M | $1.1M | -$15.0M | -$3.7M | -$14.6M | -$9.4M |
More on CLGN.
- CollPlant Biotechnologies Ltd summary
- CollPlant Biotechnologies Ltd financial statements
- CollPlant Biotechnologies Ltd key metrics
- CollPlant Biotechnologies Ltd health scores and style box
- CollPlant Biotechnologies Ltd earnings
- CollPlant Biotechnologies Ltd dividends
- CollPlant Biotechnologies Ltd valuation
- CollPlant Biotechnologies Ltd ownership and insiders
- CollPlant Biotechnologies Ltd peers
Figures from CollPlant Biotechnologies Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.